TABLE 2: CAPITAL STRUCTURE - DEC 2021
Balance sheet - Step 1 (Table 2(b)) (Figures in SAR 000's)
Balance sheet in | Adjustment of banking | Under regulatory | |
Published financial | associates / other | scope of | |
statements | entities (*) | consolidation | |
( C ) | ( D ) | ( E ) | |
Assets | |||
Cash and balances at central banks | 9,795,068 | 9,795,068 | |
Due from banks and other financial institutions | 5,323,964 | 5,323,964 | |
Investments, net | 43,858,241 | 43,858,241 | |
Positive fair value derivative | 4,061,987 | 4,061,987 | |
Loans and advances, net | 147,812,759 | 147,812,759 | |
Investment in associates | 9,695 | 9,695 | |
Property and equipment, net | 1,585,763 | 1,585,763 | |
Other assets | 3,354,549 | 3,354,549 | |
Total assets | 215,802,026 | 0 | 215,802,026 |
Liabilities
Due to SAMA & Banks and other financial institutions
Customer deposits
Negative fair value derivative Debt securities in issue Other liabilities
Total liabilities
Equity
23,853,857 | 23,853,857 | |
141,950,208 | 141,950,208 | |
3,246,098 | 3,246,098 | |
0 | 0 | |
7,066,193 | 7,066,193 | |
176,116,356 | 0 | 176,116,356 |
Paid up share capital | 12,053,572 | 12,053,572 | |
Statutory reserves | 12,053,572 | 12,053,572 | |
General reserve | 982,857 | 982,857 | |
Other reserves | 228,707 | 228,707 | |
Retained earnings | 8,398,887 | 8,398,887 | |
Minority Interest | 0 | 0 | |
Treasury shares | (51,881) | (51,881) | |
Proposed dividend | 1,019,956 | 1,019,956 | |
Tier 1 Sukuk | 5,000,000 | 5,000,000 | |
Total liabilities and equity | 215,802,026 | 0 | 215,802,026 |
Public | Page 1 of 5 |
TABLE 2: CAPITAL STRUCTURE - DEC 2021
Balance sheet - Step 2 (Table 2(c)) (Figures in SAR 000's)
Balance sheet in | Adjustment of | Under regulatory | ||
Published financial | banking associates / | scope of | ||
statements | other entities | consolidation | Reference | |
( C ) | ( D ) | ( E ) | ||
Assets | ||||
Cash and balances at central banks | 9,795,068 | 9,795,068 | ||
Due from banks and other financial institutions | 5,323,964 | 5,323,964 | ||
of which eligible provisions | 180 | 180 | A | |
Investments, net | 43,858,241 | 43,858,241 | ||
of which eligible provisions | 20,639 | 20,639 | A | |
Positive fair value derivative | 4,061,987 | 4,061,987 | ||
Loans and advances, net | 147,812,759 | 147,812,759 | ||
of which eligible provisions | 2,355,433 | 2,355,433 | A | |
Investment in associates | 9,695 | 9,695 | ||
Property and equipment, net | 1,585,763 | 1,585,763 | ||
Other assets | 3,354,549 | 3,354,549 | ||
of which eligible provisions | 545 | 545 | A | |
Total assets | 215,802,026 | 0 | 215,802,026 | |
Liabilities | ||||
Due to Banks and other financial institutions | 23,853,857 | 23,853,857 | ||
Customer deposits | 141,950,208 | 141,950,208 | ||
Negative fair value derivative | 3,246,098 | 3,246,098 | ||
Debt securities in issue | 0 | 0 | ||
of which Tier 2 capital instruments | 0 | 0 | B | |
Other liabilities | 7,066,193 | 7,066,193 | ||
of which eligible provisions | 32,353 | 32,353 | A | |
Total liabilities | 176,116,356 | 0 | 176,116,356 | |
Equity | ||||
Paid up share capital | 12,053,572 | 12,053,572 | ||
of which amount eligible for CET1 | 12,053,572 | 12,053,572 | C | |
of which amount eligible for AT1 | 0 | 0 | ||
Statutory reserves | 12,053,572 | 12,053,572 | D | |
General reserve | 982,857 | 982,857 | E | |
Other reserves | 228,707 | 228,707 | F | |
Retained earnings | 8,398,887 | 8,398,887 | G | |
SAMA supervisory provision adjustment | 862,875 | 862,875 | H | |
Minority Interest | 0 | 0 | ||
Treasury shares | (51,881) | (51,881) | ||
Proposed dividends | 1,019,956 | 1,019,956 | I | |
Tier 1 Sukuk | 5,000,000 | 5,000,000 | J | |
Total liabilities and equity | 215,802,026 | 0 | 215,802,026 | |
Public | Page 2 of 5 |
TABLE 2: CAPITAL STRUCTURE - DEC 2021
Common template (transition) - Step 3 (Table 2(d)) I (Figures in SAR 000's)
(From January 2013 to 2018 identical to post 2018) With amount subject to Pre- Basel III Treatment
Source based on | |||||||||||
reference | |||||||||||
Amounts1 | numbers / letters | ||||||||||
Components1 of | of the balance | ||||||||||
subject to | sheet under the | ||||||||||
regulatory | Pre - | regulatory scope | |||||||||
capital reported | Basel III | of consolidation | |||||||||
by the bank | treatment | from step 2 | |||||||||
Common Equity Tier 1 capital: Instruments and reserves | |||||||||||
1 | Directly issued qualifying common share capital (and equivalent for non-joint stock companies) plus | 12,053,572 | |||||||||
related stock surplus | C | ||||||||||
2 | Retained earnings (including Statutory and General reserves) | 23,318,147 | D+E+G+I+H | ||||||||
3 | Accumulated other comprehensive income (and other reserves) | 228,707 | F | ||||||||
4 | Directly issued capital subject to phase out from CET1 (only applicable to non-joint stock companies) | - | |||||||||
5 | Common share capital isued by subsidiaries and held by third parties (amount allowed in group CET1) | - | - | ||||||||
6 | Common Equity Tier 1 capital before regulatory adjustments | 35,600,426 | |||||||||
Common Equity Tier 1 capital: Regulatory adjustments | |||||||||||
7 | Prudential valuation adjustments | - | - | ||||||||
8 | Goodwill (net of related tax liability) | - | - | ||||||||
9 | Other intangibles other than mortgage-servicing rights (net of related tax liability) | - | - | ||||||||
10 | Deferred tax assets that rely on future profitability excluding those arising from temporary differences | - | |||||||||
(net of related tax liability) | - | ||||||||||
11 | Cash-flow hedge reserve | (219,264) | - | ||||||||
12 | Shortfall of provisions to expected losses | - | - | ||||||||
13 | Securitisation gain on sale (as set out in paragraph 562 of Basel II framework) | - | - | ||||||||
14 | Gains and losses due to changes in own credit risk on fair valued liabilities | - | - | ||||||||
15 | Defined-benefit pension fund net assets | - | - | ||||||||
16 | Investments in own shares (if not already netted off paid-in capital on reported balance sheet) | (51,881) | - | ||||||||
17 | Reciprocal cross-holdings in common equity | - | - | ||||||||
18 | Investments in the capital of banking, financial and insurance entities that are outside the scope of | ||||||||||
regulatory consolidation, net of eligible short positions, where the bank does not own more than 10% of | - | ||||||||||
the issued share capital (amount above 10% threshold) | - | ||||||||||
19 | Significant investments in the common stock of banking, financial and insurance entities that are | ||||||||||
outside the scope of regulatory consolidation, net of eligible short positions (amount above 10% | - | ||||||||||
threshold) | - | ||||||||||
20 | Mortgage servicing rights (amount above 10% threshold) | - | - | ||||||||
21 | Deferred tax assets arising from temporary differences (amount above 10% threshold, net of related | - | |||||||||
tax liability) | - | ||||||||||
22 | Amount exceeding the 15% threshold | - | - | ||||||||
23 | of which: significant investments in the common stock of financials | - | - | ||||||||
24 | of which: mortgage servicing rights | - | - | ||||||||
25 | of which: deferred tax assets arising from temporary differences | - | - | ||||||||
26 | National specific regulatory adjustments | - | - | ||||||||
REGULATORY ADJUSTMENTS APPLIED TO COMMON EQUITY TIER 1 IN RESPECT OF | |||||||||||
AMOUNTS SUBJECT TO PRE-BASEL III TREATMENT | - | ||||||||||
OF WHICH: [INSERT NAME OF ADJUSTMENT] | - | ||||||||||
OF WHICH:… | - | ||||||||||
27 | Regulatory adjustments applied to Common Equity Tier 1 due to insufficient Additional Tier 1 and Tier 2 | - | |||||||||
to cover deductions | |||||||||||
28 | Total regulatory adjustments to Common equity Tier 1 | (271,145) | |||||||||
29 | Common Equity Tier 1 capital (CET1) | 35,329,281 | |||||||||
Additional Tier 1 capital: instruments | |||||||||||
30 | Directly issued qualifying Additional Tier 1 instruments plus related stock surplus | 5,000,000 | J | ||||||||
31 | of which: classified as equity under applicable accounting standards | - | |||||||||
32 | of which: classified as liabilities under applicable accounting standards | - | |||||||||
33 | Directly issued capital instruments subject to phase out from Additional Tier 1 | - | |||||||||
34 | Additional Tier 1 instruments (and CET1 instruments not included in row 5) issued by subsidiaries and | - | |||||||||
held by third parties (amount allowed in group AT1) | |||||||||||
35 | of which: instruments issued by subsidiaries subject to phase out | - | |||||||||
36 | Additional Tier 1 capital before regulatory adjustments | 5,000,000 | |||||||||
Additional Tier 1 capital: regulatory adjustments | |||||||||||
37 | Investments in own Additional Tier 1 instruments | - | - | ||||||||
38 | Reciprocal cross-holdings in Additional Tier 1 instruments | - | - | ||||||||
39 | Investments in the capital of banking, financial and insurance entities that are outside the scope of | ||||||||||
regulatory consolidation, net of eligible short positions, where the bank does not own more than 10% of | |||||||||||
the issued common share capital of the entity (amount above 10% threshold) | - | - | |||||||||
40 | Significant investments in the capital of banking, financial and insurance entities that are outside the | ||||||||||
scope of regulatory consolidation (net of eligible short positions) | - | - | |||||||||
41 | National specific regulatory adjustments | - | |||||||||
REGULATORY ADJUSTMENTS APPLIED TO ADDITIONAL TIER 1 IN RESPECT OF AMOUNTS | |||||||||||
SUBJECT TO PRE-BASEL III TREATMENT | - | ||||||||||
OF WHICH: [INSERT NAME OF ADJUSTMENT] | - | ||||||||||
OF WHICH: … | - | ||||||||||
42 | Regulatory adjustments applied to Additional Tier 1 due to insufficient Tier 2 to cover deductions | - | |||||||||
43 | Total regulatory adjustments to Additional Tier 1 capital | - | |||||||||
44 | Additional Tier 1 capital (AT1) | 5,000,000 | |||||||||
45 | Tier 1 capital (T1 = CET1 + AT1) | 40,329,281 |
Public | Page 3 of 5 |
TABLE 2: CAPITAL STRUCTURE - DEC 2021
Common template (transition) - Step 3 (Table 2(d)) ii (Figures in SAR 000's)
(From January 2013 to 2018 identical to post 2018) With amount subject to Pre- Basel III Treatment
Amounts1 | Source based on reference | |||||||||||
Components1 of | numbers / letters of the | |||||||||||
subject to | balance sheet under the | |||||||||||
regulatory capital | Pre - Basel | regulatory scope of | ||||||||||
reported by the bank | III treatment consolidation from step 2 | |||||||||||
Tier 2 capital: instruments and provisions | ||||||||||||
46 | Directly issued qualifying Tier 2 instruments plus related stock surplus | 0 | B | |||||||||
47 | Directly issued capital instruments subject to phase out from Tier 2 | 0 | ||||||||||
48 | Tier 2 instruments (and CET1 and AT1 instruments not included in rows 5 or 34) issued by subsidiaries | - | ||||||||||
and held by third parties (amount allowed in group Tier 2) | ||||||||||||
49 | of which: instruments issued by subsidiaries subject to phase out | - | ||||||||||
50 | Provisions | 2,314,491 | ||||||||||
51 | Tier 2 capital before regulatory adjustments | 2,314,491 | ||||||||||
Tier 2 capital: regulatory adjustments | ||||||||||||
52 | Investments in own Tier 2 instruments | - | - | |||||||||
53 | Reciprocal cross-holdings in Tier 2 instruments | - | - | |||||||||
54 | Investments in the capital of banking, financial and insurance entities that are outside the scope of | |||||||||||
regulatory consolidation, net of eligible short positions, where the bank does not own more than 10% of | - | |||||||||||
the issued common share capital of the entity (amount above the 10% threshold) | - | |||||||||||
55 | Significant investments in the capital banking, financial and insurance entities that are outside the | - | ||||||||||
scope of regulatory consolidation (net of eligible short positions) | - | |||||||||||
56 | National specific regulatory adjustments | |||||||||||
REGULATORY ADJUSTMENTS APPLIED TO TIER 2 IN RESPECT OF AMOUNTS SUBJECT TO | - | |||||||||||
PRE-BASEL III TREATMENT | ||||||||||||
OF WHICH: [INSERT NAME OF ADJUSTMENT] | - | |||||||||||
OF WHICH: … | - | |||||||||||
57 | Total regulatory adjustments to Tier 2 capital | 0 | ||||||||||
58 | Tier 2 capital (T2) | 2,314,491 | ||||||||||
59 | Total capital (TC = T1 + T2) | 42,643,772 | ||||||||||
RISK WEIGHTED ASSETS IN REPECT OF AMOUNTS SUBJECT TO PRE-BASEL III TREATMENT | - | |||||||||||
OF WHICH: [INSERT NAME OF ADJUSTMENT] | - | |||||||||||
OF WHICH: … | - | |||||||||||
60 | Total risk weighted assets | 202,219,816 | ||||||||||
Capital ratios | ||||||||||||
61 | Common Equity Tier 1 (as a percentage of risk weighted assets) | 17.47% | ||||||||||
62 | Tier 1 (as a percentage of risk weighted assets) | 19.94% | ||||||||||
63 | Total capital (as a percentage of risk weighted assets) | 21.09% | ||||||||||
64 | Institution specific buffer requirement (minimum CET1 requirement plus capital conservation buffer plus | |||||||||||
countercyclical buffer requirements plus G-SIB buffer requirement expressed as a percentage of risk | ||||||||||||
weighted assets) | 7.560% | |||||||||||
65 | of which: capital conservation buffer requirement | 2.500% | ||||||||||
66 | of which: bank specific countercyclical buffer requirement | 0.060% | ||||||||||
67 | of which: G-SIB/D-SIB buffer requirement | 0.500% | ||||||||||
68 | Common Equity Tier 1 available to meet buffers (as a percentage of risk weighted assets) | 15.443% | ||||||||||
National minima (if different from Basel 3) | ||||||||||||
69 | National Common Equity Tier 1 minimum ratio (if different from Basel 3 minimum) | n/a | ||||||||||
70 | National Tier 1 minimum ratio (if different from Basel 3 minimum) | n/a | ||||||||||
71 | National total capital minimum ratio (if different from Basel 3 minimum) | n/a | ||||||||||
Amounts below the thresholds for deduction (before risk weighting) | ||||||||||||
72 | Non-significant investments in the capital of other financials | - | ||||||||||
73 | Significant investments in the common stock of financials | - | ||||||||||
74 | Mortgage servicing rights (net of related tax liability) | - | ||||||||||
75 | Deferred tax assets arising from temporary differences (net of related tax liability) | - | ||||||||||
Applicable caps on the inclusion of provisions in Tier 2 | ||||||||||||
76 | Provisions eligible for inclusion in Tier 2 in respect of exposures subject to standardised approach | |||||||||||
(prior to application of cap) | 2,409,150 | A | ||||||||||
77 | Cap on inclusion of provisions in Tier 2 under standardised approach | 2,314,491 | ||||||||||
78 | Provisions eligible for inclusion in Tier 2 in respect of exposures subject to internal ratings-based | |||||||||||
approach (prior to application of cap) | n/a | |||||||||||
79 | Cap for inclusion of provisions in Tier 2 under internal ratings-based approach | n/a | ||||||||||
Capital instruments subject to phase-out arrangements (only applicable between 1 Jan 2018 | ||||||||||||
and 1 Jan 2022) | ||||||||||||
80 | Current cap on CET1 instruments subject to phase out arrangements | - | ||||||||||
81 | Amount excluded from CET1 due to cap (excess over cap after redemptions and maturities) | - | ||||||||||
82 | Current cap on AT1 instruments subject to phase out arrangements | - | ||||||||||
83 | Amount excluded from AT1 due to cap (excess over cap after redemptions and maturities) | - | ||||||||||
84 | Current cap on T2 instruments subject to phase out arrangements | - | ||||||||||
85 | Amount excluded from T2 due to cap (excess over cap after redemptions and maturities) | - | ||||||||||
Public | Page 4 of 5 |
TABLE 2: CAPITAL STRUCTURE - DEC 2021
Main features template of regulatory capital instrument - (Table 2(e))
Components1 of regulatory | ||
capital reported by the bank | ||
1 | Issuer | Banque Saudi Fransi |
2 | Unique identifier | N/A |
3 | Governing law(s) of the instrument | Saudi Arabian law |
Regulatory treatment | ||
4 | Transitional Basel III rules | Additional Tier I |
5 | Post-transitional Basel III rules | Eligible |
6 | Eligible at solo/group/group & solo | Group & Solo |
7 | Instrument type | Subordinated sukuk |
8 | Amount recognied in regulatory capital (in SAR 000' s) | SAR 5,000,000 |
9 | Par value of instrument (in SAR 000' s) | SAR 5,000,000 |
10 | Accounting classification | Equity |
11 | Original date of issuance | 04 November 2020 |
12 | Perpetual or dated | Perpetual |
13 | Original maturity date | N/A |
14 | Issuer call subject to prior supervisory approval | Yes |
In compliance with Basel III, call | ||
date is equal to or greater than 5 | ||
years and the Sukuk may be | ||
redeemed early due to a capital | ||
event, tax event or at the option | ||
of the Bank as described in the | ||
terms and conditions of the | ||
15 | Option call date, contingent call dates and redemption amount | Sukuk |
16 | Subsequent call dates if applicable | As above |
Coupons / dividends | ||
17 | Fixed or Floating dividend/coupon | Fixed |
18 | Coupon rate and any related index | 4.5% p.a. |
19 | Existence of a dividend stopper | Yes |
20 | Fully discretionary, partially discretionary or mandatory | Fully discretionary |
21 | Existence of step up or other incentive to redeem | No |
22 | Non cumulative or cumulative | Non Cumulative |
23 | Convertible or non-convertible | Non Convertible |
24 | If convertible, conversion trigger (s) | N/A |
25 | If convertible, fully or partially | N/A |
26 | If convertible, conversion rate | N/A |
27 | If convertible, mandatory or optional conversion | N/A |
28 | If convertible, specify instrument type convertible into | N/A |
29 | If convertible, specify issuer of instrument it converts into | N/A |
30 | Write-down feature | Yes |
Terms of contract of the | ||
instrument provide the | ||
legal basis for SAMA to trigger | ||
write-down (a | ||
31 | If write-down,write-down trigger (s) | contractual approach) |
32 | If write-down, full or partial | Write-down fully or partial |
33 | If write-down, permanent or temporary | Permanent |
34 | If temporary writedown, description of the write-up mechansim | N/A |
Position in subordination hierarchy in liquidation (specify instrument type | ||
35 | immediately senior to instrument) | Subordinated |
36 | Non-compliant transitioned features | N/A |
37 | If yes, specify non-compliant features | N/A |
Public | Page 5 of 5 |